Taking a Fresh Look at Ventas, Inc. (VTR)

Ventas, Inc. (VTR) is an interesting player in the Financial space, with a focus on REIT – Healthcare Facilities. The stock has been active on the tape, currently trading at $60.01, down from yesterday’s close by -0.70%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.

Fundamental Analysis

Ventas, Inc. (VTR) currently trades with a market capitalization of $21.52 Billion. That value represents a market adjusting for revenues that have been growing by 3.78 % on a quarterly year/year basis as of the company’s last quarterly report.

You can get a sense of how sustainable that is by a levered free cash flow of $941.51 Million over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of $0.71 on a per share basis this quarter. Perhaps, that suggests something about why 0.65% of the outstanding share supply is held by institutional investors.

Technical Analysis

It’s important to check the technicals to get a sense of how VTR has been acting. Looking at the stock’s movement on the chart, Ventas, Inc. recorded a 52-week high of $72.36. It is now trading 12.35% off that level. The stock is trading $63.17 its 50-day moving average by 3.16%. The stock carved out a 52-week low down at $58.96.

In recent action, Ventas, Inc. (VTR) has made a move of -6.25% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 19.03, and it’s gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 2.02% with $354.66 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of VTR.

Previous articleEldorado Gold Corporation (EGO): From Top to Bottom
Next articleDrilling Down Into Eli Lilly and Company (LLY)